Xenetic Biosciences, Inc. (NASDAQ:XBIO)

BRIEF

published on 03/26/2025 at 14:05, 8 days 7 hours ago

Le partenaire de Xenetic Biosciences participe à une étude clinique pour développer sa plateforme DNase

Traitement Du Cancer Étude Clinique Biosciences Xénétiques Plateforme DNase Ostéosarcome
BRIEF

published on 03/26/2025 at 14:05, 8 days 7 hours ago

Xenetic Biosciences' Partner Enters Clinical Study to Advance DNase Platform

Xenetic Biosciences Cancer Treatment Clinical Study DNase Platform Osteosarcoma
PRESS RELEASE

published on 03/26/2025 at 14:00, 8 days 7 hours ago

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma
Xenetic Biosciences, Inc. collaborates with PeriNess Ltd. on a clinical study at Tel-Aviv Sourasky Medical Center to evaluate DNase I candidate XBIO-015 in osteosarcoma and Ewing sarcoma patients

Xenetic Biosciences Clinical Study DNase I PeriNess Ltd. Osteosarcoma
BRIEF

published on 03/19/2025 at 13:10, 15 days 8 hours ago

Xenetic Biosciences publie ses résultats financiers pour 2024

Résultats Financiers Développement Clinique Collaborations Traitement Du Cancer Technologie DNase
BRIEF

published on 03/19/2025 at 13:10, 15 days 8 hours ago

Xenetic Biosciences Reports 2024 Financial Results

Financial Results Cancer Treatment Clinical Development Collaborations DNase Technology
PRESS RELEASE

published on 03/19/2025 at 13:05, 15 days 8 hours ago

Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results
Xenetic Biosciences reports encouraging preclinical data on DNase-based technology targeting NETosis for difficult cancers. Focus on clinical studies partnerships and DNase I development program for pancreatic carcinoma

Xenetic Biosciences Preclinical Data Clinical Studies DNase-based Technology NETosis
BRIEF

published on 03/13/2025 at 13:35, 21 days 8 hours ago

Xenetic Biosciences Reveals Promising Preclinical Data for DNase I in Cancer Therapy

Xenetic Biosciences Cancer Treatment Preclinical Data DNase I Therapy CAR T Cells
BRIEF

published on 03/13/2025 at 13:35, 21 days 8 hours ago

Xenetic Biosciences révèle des données précliniques prometteuses sur l'ADNase I dans le traitement du cancer

Traitement Du Cancer Biosciences Xénétiques Données Précliniques Cellules CAR-T Thérapie À La DNase I
PRESS RELEASE

published on 03/13/2025 at 13:30, 21 days 8 hours ago

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses
Xenetic Biosciences presents promising findings on combining DNase I with CAR T cells to enhance cancer treatment strategies at the SITC Spring Scientific 2025 Cell Therapy Meeting

Xenetic Biosciences Cancer Treatment DNase I CAR T Cells SITC Spring Meeting
BRIEF

published on 02/27/2025 at 15:20, 1 month 4 days ago

Xenetic Biosciences' Abstract Accepted for SITC 2025 Meeting

Xenetic Biosciences Immuno-oncology Cell Therapy DNase Platform SITC 2025

1 2 ... 6

Published on 04/03/2025 at 15:05, 6 hours 51 minutes ago

Snowline Gold Closes Fully Subscribed C$20 Million Financing Of Flow-Through Shares
Published on 04/03/2025 at 15:00, 6 hours 56 minutes ago

Kingstone Insurance Partners with Kyber Technologies Inc.
Published on 04/03/2025 at 15:00, 6 hours 56 minutes ago

UniDoc Announces Debt Settlement and Renews Marketing Engagement
Published on 04/03/2025 at 15:00, 6 hours 56 minutes ago

Xebra Brands’ Largest Shareholder Increases Stake as Company Explores Landmark Agricultural Agreement in Mexico
Published on 04/03/2025 at 14:30, 7 hours 26 minutes ago

Dominari Holdings Highlights Supporting American Companies

View all ACCESSWIRE

Published on 04/03/2025 at 19:37, 2 hours 19 minutes ago

Changes to Sub-Funds
Published on 04/03/2025 at 19:32, 2 hours 24 minutes ago

Changes to Sub-Funds
Published on 04/03/2025 at 19:22, 2 hours 34 minutes ago

Changes to Sub-Funds
Published on 04/03/2025 at 19:11, 2 hours 45 minutes ago

Changes to Sub-Funds
Published on 04/03/2025 at 19:00, 2 hours 56 minutes ago

Changes to Sub-Funds

View all EQS

Published on 04/03/2025 at 18:46, 3 hours 10 minutes ago

Monthly disclosure of the total number of shares and voting rights - March 2025
Published on 04/03/2025 at 18:46, 3 hours 10 minutes ago

Déclaration mensuelle des actions et droits de vote – Mars 2025
Published on 04/03/2025 at 18:00, 3 hours 56 minutes ago

LDC : Chiffre d'affaires 2024-2025 : 6,3 milliards d’euros, au-delà des objectifs.
Published on 04/03/2025 at 17:45, 4 hours 11 minutes ago

CDA - Acquisition of Belantis park
Published on 04/03/2025 at 17:45, 4 hours 11 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

View all LES ECHOS COMFI WIRE

News